白细胞分离法治疗溃疡性结肠炎的研究进展

溃疡性结肠炎(UC)是一种慢性非特异性肠道炎性疾病,其发病机制尚未完全明确。该病的治疗一直是一个难题,部分难治性UC患者在传统药物治疗无效的情况下需转为外科手术治疗。近年来随着人们对UC发病机制的深入研究,选择性白细胞分离法(LCAP)逐渐成为治疗UC的有效方法之一。此文就LCAP治疗UC的研究进展作一综述。     

白细胞分离法在溃疡性结肠炎中的应用

白细胞分离法(LCAP)是一种新型血液净化技术,其在溃疡性结肠炎的治疗中显示出较好的临床效果.LCAP可获得较高的临床缓解率,并在促进黏膜修复及维持长期缓解中起到一定作用,同时其具有较好的安全性.LCAP的临床价值有待于进一步的研究.     

抗肿瘤坏死因子α制剂治疗溃疡性结肠炎的荟萃分析

目的 根据现有临床研究评价抗TNFα制剂治疗溃疡性结肠炎(UC)的疗效与安全性.方法 检索Cochrane图书馆、EMBASE、PubMed、OVID数据库和中国知网、万方数据库、维普数据库中有关抗TNFa制剂[英夫利西单抗、阿达木单抗、塞妥珠单抗、依那西普、奥那西普、CDP571、CNI-1493、沙利度胺]治疗UC的RCT文献,采用Revman 5.0软件进行分析,并绘制漏斗图评定有无发表偏倚.结果 共9项RCT研究符合纳入标准,共包括1226例UC患者,其中806例接受抗TNFα制剂治疗,420例接受安慰剂或其他对照药物治疗.荟萃分析显示,在短期应答、短期缓解、长期应答、长期缓解方面,抗TNFα制剂明显优于对照组,OR值分别为2.36(95%CI 1.34～4.15)、2.42(95%CI 1.22～4.81)、3.22(95%CI 2.28～4.55)、2.82(95%CI 1.91～4.16).与对照组相比,抗TNFα制剂可以降低结肠切除率,OR值为0.31(95%CI 0.20～0.48);但在结肠黏膜愈合方面[OR值为1.59(95%CI 0.91～2.78)]及生活质量方面[炎症性肠病问卷(IBDQ)评分的加权均数差(WMD)为24.00(95%CI为-0.95～48.95)],两组的差异均无统计学意义.在安全性方面,两组不良反应发生率相似,OR值为1.07(95%CI0.55～2.09,P=0.84),但抗TNFα制剂的重度不良反应发生率明显低于对照组,OR值为0.65(95%CI 0.48～0.89).各计数资料观察指标的漏斗图均基本呈现下宽上窄、左右对称的图形,提示无发表偏倚.结论 抗TNFα制剂对于常规药物治疗无效的中、重度UC有较好的疗效,可以诱导UC短期应答,降低结肠切除率,并可维持长期的临床应答与临床缓解,严重不良反应的发生率较低,但抗TNFα制剂未能提高UC患者的生活质量与黏膜愈合率.

Abstract：

Objective To pool the data of studies and evaluate the efficacy and safety of TNFα blocking agents in the treatment of ulcerative colitis(UC).Methods The randomized clinical trials(RCT)that compared the efficacy or safety of TNFα in the treatment of UC were researched from Pubmed. OVID. EMBASE. Cochrane library, CNKI, Wanfang data and VIP Chinese Scientific and Technologic Periodical Database. Statistical heterogeneity between trials was evaluated by Revman 5.0 and was considered to exist when P＜0.1.Heterogeneity of the included articles was tested. which was used to select proper effect model to calculate. Publication bias was investigated through visual inspection of funnel plots. Results Nine RCT including 1226 cases were analyzed. Eight hundred and six cases had received TNFα treatment and 420cases had received placebo or glucocorticoid treatment. Compared with placebo or glucocorticoid groups, TNFα group achieved significantly higher rates of short-term clinical response, short-term clinical remission, long-term clinical response.10ng-term clinical remission and the total OR were 2.36(95%C,1.34-4.15),2.42(95%CI 1.22-4.81).3.22(95%CI2.28-4.55)and 2.82(95%CI1.91-4.16)respectively. TNFα group was less likely to undergo colectomy than placebo group and the total OR was 0.31(95%CI0.20-0.48).TNFα could not improve the mucosal healing and quality of lire. No significant difference was found in adverse effect between TNFα group and placebo or glueoeortieoid group(OR=1.07(95%CI0.55-2.09,P=0.84)).The rate of serious adverse effect in TNFα group was less than placebo or glueoeorticoid groups (OR=0.65,95%CI0.48-0.89,P=0.007).Inspection of the funnel plots for all dichotomous data measures had not revealed evidence of publication bias. Conclusions Patients with moderately to severely active UC treated with TNFαhave effective clinical response and clinical remission and are less likely to undergo colectomy than those receiving placebo or glucocorticoid. TNFα treatment is safe for UC but can not improve the mucosal healing and quality of life. Large-scale, high-quality RCTs ale needed to confirm or refuse the available evidence.     

选择性白细胞吸附疗法治疗溃疡性结肠炎的疗效及安全性分析

目的探讨选择性白细胞吸附疗法(granulocyte and monocyte adsorption apheresis,GMA)治疗溃疡性结肠炎(ulcerative colitis,UC)的疗效及安全性。方法回顾性收集2018年5月至2019年5月在山东中医药大学第二附属医院行GMA治疗的18例UC患者的临床资料,所有入组患者均行1周2次、5次为1个疗程的治疗方案,重度患者适当延长疗程,分析治疗前、治疗1个疗程后的内镜检查、改良Mayo评分、红细胞沉降率(ESR)、C-反应蛋白(CRP)、白细胞计数(WBC)、中性粒细胞计数(NEUT)、白蛋白(ALB)、血红蛋白(HGB),同时观察患者治疗后的不良反应。结果与治疗前比较,GMA治疗1个疗程结束后,改良Mayo评分、ESR、CRP均显著降低(P<0.05),ALB、HGB均显著升高(P<0.05),WBC、NEUT差异无统计学意义(P>0.05)。18例患者在GMA治疗过程中及治疗后均无明显不良反应发生,安全性良好。结论GMA可明显降低炎症活动度及改善临床症状,且不良反应发生率较低,具有良好的疗效及安全性。     

抗肿瘤坏死因子α制剂治疗溃疡性结肠炎的荟萃分析

Objective To pool the data of studies and evaluate the efficacy and safety of TNFα blocking agents in the treatment of ulcerative colitis(UC).Methods The randomized clinical trials(RCT)that compared the efficacy or safety of TNFα in the treatment of UC were researched from Pubmed. OVID. EMBASE. Cochrane library, CNKI, Wanfang data and VIP Chinese Scientific and Technologic Periodical Database. Statistical heterogeneity between trials was evaluated by Revman 5.0 and was considered to exist when P＜0.1.Heterogeneity of the included articles was tested. which was used to select proper effect model to calculate. Publication bias was investigated through visual inspection of funnel plots. Results Nine RCT including 1226 cases were analyzed. Eight hundred and six cases had received TNFα treatment and 420cases had received placebo or glucocorticoid treatment. Compared with placebo or glucocorticoid groups, TNFα group achieved significantly higher rates of short-term clinical response, short-term clinical remission, long-term clinical response.10ng-term clinical remission and the total OR were 2.36(95%C,1.34-4.15),2.42(95%CI 1.22-4.81).3.22(95%CI2.28-4.55)and 2.82(95%CI1.91-4.16)respectively. TNFα group was less likely to undergo colectomy than placebo group and the total OR was 0.31(95%CI0.20-0.48).TNFα could not improve the mucosal healing and quality of lire. No significant difference was found in adverse effect between TNFα group and placebo or glueoeortieoid group(OR=1.07(95%CI0.55-2.09,P=0.84)).The rate of serious adverse effect in TNFα group was less than placebo or glueoeorticoid groups (OR=0.65,95%CI0.48-0.89,P=0.007).Inspection of the funnel plots for all dichotomous data measures had not revealed evidence of publication bias. Conclusions Patients with moderately to severely active UC treated with TNFαhave effective clinical response and clinical remission and are less likely to undergo colectomy than those receiving placebo or glucocorticoid. TNFα treatment is safe for UC but can not improve the mucosal healing and quality of life. Large-scale, high-quality RCTs ale needed to confirm or refuse the available evidence.     

抗肿瘤坏死因子α制剂治疗溃疡性结肠炎的荟萃分析

Objective To pool the data of studies and evaluate the efficacy and safety of TNFα blocking agents in the treatment of ulcerative colitis(UC).Methods The randomized clinical trials(RCT)that compared the efficacy or safety of TNFα in the treatment of UC were researched from Pubmed. OVID. EMBASE. Cochrane library, CNKI, Wanfang data and VIP Chinese Scientific and Technologic Periodical Database. Statistical heterogeneity between trials was evaluated by Revman 5.0 and was considered to exist when P＜0.1.Heterogeneity of the included articles was tested. which was used to select proper effect model to calculate. Publication bias was investigated through visual inspection of funnel plots. Results Nine RCT including 1226 cases were analyzed. Eight hundred and six cases had received TNFα treatment and 420cases had received placebo or glucocorticoid treatment. Compared with placebo or glucocorticoid groups, TNFα group achieved significantly higher rates of short-term clinical response, short-term clinical remission, long-term clinical response.10ng-term clinical remission and the total OR were 2.36(95%C,1.34-4.15),2.42(95%CI 1.22-4.81).3.22(95%CI2.28-4.55)and 2.82(95%CI1.91-4.16)respectively. TNFα group was less likely to undergo colectomy than placebo group and the total OR was 0.31(95%CI0.20-0.48).TNFα could not improve the mucosal healing and quality of lire. No significant difference was found in adverse effect between TNFα group and placebo or glueoeortieoid group(OR=1.07(95%CI0.55-2.09,P=0.84)).The rate of serious adverse effect in TNFα group was less than placebo or glueoeorticoid groups (OR=0.65,95%CI0.48-0.89,P=0.007).Inspection of the funnel plots for all dichotomous data measures had not revealed evidence of publication bias. Conclusions Patients with moderately to severely active UC treated with TNFαhave effective clinical response and clinical remission and are less likely to undergo colectomy than those receiving placebo or glucocorticoid. TNFα treatment is safe for UC but can not improve the mucosal healing and quality of life. Large-scale, high-quality RCTs ale needed to confirm or refuse the available evidence.     

抗肿瘤坏死因子α制剂治疗溃疡性结肠炎的荟萃分析

Objective To pool the data of studies and evaluate the efficacy and safety of TNFα blocking agents in the treatment of ulcerative colitis(UC).Methods The randomized clinical trials(RCT)that compared the efficacy or safety of TNFα in the treatment of UC were researched from Pubmed. OVID. EMBASE. Cochrane library, CNKI, Wanfang data and VIP Chinese Scientific and Technologic Periodical Database. Statistical heterogeneity between trials was evaluated by Revman 5.0 and was considered to exist when P＜0.1.Heterogeneity of the included articles was tested. which was used to select proper effect model to calculate. Publication bias was investigated through visual inspection of funnel plots. Results Nine RCT including 1226 cases were analyzed. Eight hundred and six cases had received TNFα treatment and 420cases had received placebo or glucocorticoid treatment. Compared with placebo or glucocorticoid groups, TNFα group achieved significantly higher rates of short-term clinical response, short-term clinical remission, long-term clinical response.10ng-term clinical remission and the total OR were 2.36(95%C,1.34-4.15),2.42(95%CI 1.22-4.81).3.22(95%CI2.28-4.55)and 2.82(95%CI1.91-4.16)respectively. TNFα group was less likely to undergo colectomy than placebo group and the total OR was 0.31(95%CI0.20-0.48).TNFα could not improve the mucosal healing and quality of lire. No significant difference was found in adverse effect between TNFα group and placebo or glueoeortieoid group(OR=1.07(95%CI0.55-2.09,P=0.84)).The rate of serious adverse effect in TNFα group was less than placebo or glueoeorticoid groups (OR=0.65,95%CI0.48-0.89,P=0.007).Inspection of the funnel plots for all dichotomous data measures had not revealed evidence of publication bias. Conclusions Patients with moderately to severely active UC treated with TNFαhave effective clinical response and clinical remission and are less likely to undergo colectomy than those receiving placebo or glucocorticoid. TNFα treatment is safe for UC but can not improve the mucosal healing and quality of life. Large-scale, high-quality RCTs ale needed to confirm or refuse the available evidence.     

参苓白术散联合西药治疗溃疡性结肠炎的Meta分析

[目的]系统评价参苓白术散联合西药治疗溃疡性结肠炎(UC)的临床疗效。[方法]计算机检索中国知网(1982~2015)、万方(2001~2015)、维普(1989~2015)、读秀(1996~2015)、PUBMED(1991~2015)、PLoS公共医学科学图书馆(1991~2015)、PMC美国国家医学图书馆生命科学期刊(1991~2015)等数据库,收集参苓白术散联合西药治疗UC的随机对照试验(RCT),由2位评价者独立按照纳入与排除标准筛选文献、提取资料和评价质量后,采用RevMan5.3软件进行Meta分析。[结果]共纳入10个文献,包含884例患者。参苓白术散联合西药组在治疗UC的总有效率[OR=3.30,95%CI(2.25,4.82),P0.01]、显效率[OR=2.02,95%CI(1.54,2.65),P0.01]均优于对照组,有效率与对照组相近[OR=1.08,95%CI(0.78,1.50),P=0.64],无效率则低于对照组[OR=0.30,95%CI(0.21,0.44),P0.01]。差异有显著统计学意义。漏斗图分析不对称,表明存在发表性偏倚。[结论]参苓白术散联合西药组治疗UC的疗效优于对照组。     

噻唑烷二酮类治疗溃疡性结肠炎疗效的荟萃分析

目的采用Meta分析方法对噻唑烷二酮类药物(罗格列酮、吡格列酮)治疗溃疡性结肠炎的疗效进行系统评价。方法以"噻唑烷二酮"、"罗格列酮"、"吡格列酮"、"溃疡性结肠炎"、"随机对照试验"为检索词,检索PubMed、CNKI、WanFang Data、CBM、Google数据库,并追溯参考文献进行全面的文献检索。根据纳入与排除标准筛选文献,提取数据并评价质量,用Review Manager 4.3软件进行Meta分析,同时进行敏感性分析及发表偏倚的评估。结果本研究共纳入文献6篇,经Meta分析,噻唑烷二酮类能明显降低溃疡性结肠炎的疾病活动评分(UCAI)(WMD=-0.92,95%CI:-1.17~-0.66,P0.00001);噻唑烷二酮类明显增加溃疡性结肠炎的有效缓解人数(OR=12.31,95%CI:1.71~88.74,P=0.01);噻唑烷二酮类药物能明显改善溃疡性结肠炎的组织学分级,尤其是0~Ⅰ级(OR=2.71,95%CI:1.55~4.72,P=0.0004)。失效安全数结果显示,发表偏倚较小。敏感性分析研究表明结果稳定可靠。结论噻唑烷二酮类药物能显著提高溃疡性结肠炎的临床疗效。     

肝素治疗溃疡性结肠炎有效性的系统评价

为找到改善溃疡性结肠炎（UC）疗效的方法，已进行了许多努力。不同研究显示肝素在UC治疗中的疗效不同。目的：评价肝素是否适用于治疗UC患者。方法：对随机对照试验行荟萃分析，比较肝素治疗和传统治疗对UC患者的疗效，计算OR值，评估试验质量和异质性，并行亚型和敏感性分析。结果：最终纳入8项研究。肝素治疗组（包括普通肝素组和低分子量肝素组）的疾病缓解率与传统治疗组无显著差异（P〉0．05）。肝素治疗组的疾病缓解率与安慰剂组亦无显著差异（P〉0．05）。结论：应用肝素治疗UC患者，其疗效不优于传统治疗。     

益生菌制剂VSL#3对溃疡性结肠炎诱导缓解作用的系统评价

循证医学证据提示益生菌对溃疡性结肠炎（UC）的诱导缓解无效,但对维持缓解有效,然而2009年发表的两项临床试验结果显示益生菌合剂VSL#3对UC的诱导缓解有效。目的：系统评价益生菌尤其是VSL#3诱导UC缓解的有效性和安全性。方法：联机检索MEDLINE、EMBASE、CochraneLibrary和中国生物医学文献数据、万方数据库,由两名分析人员独立选取与UC诱导缓解相关、比较益生菌治疗组与对照组（安慰剂或阳性对照）的随机对照试验（不限语种）并提取数据。应用RevMan5．2．10软件行meta分析,同时行亚组分析和敏感性分析。结果：共纳入9项随机对照试验,共557例UC患者,其中4项治疗组使用VSL#3。Meta分析显示益生菌组总体诱导缓解率显著优于对照组（OR=2．05,95％CI：1．14～3．70,P=0．02）,亚组分析显示VSL#3亚组诱导缓解率显著优于对照组（OR：2．35,95％CI：1．45—3．80,P=0．0005）,其他菌种与对照组间诱导缓解率无明显差异。益生菌组、VSL#3亚组与对照组间不良反应发生率均无明显差异。敏感性分析显示meta分析结果稳定。结论：VSL#3对UC的诱导缓解作用优于对照组且安全性高。     

Leukocyte Apheresis Using a Centrifugal Cell Separator in Refractory Ulcerative Colitis: A Multicenter Open Label Trial

Abstract: Recently, successful results of ulcerative colitis (UC) treatments with leukocyte apheresis have been reported by several institutes. To certify the efficacy of leukocyte apheresis in refractory UC patients, a multicenter open label trial was conducted, and results were analyzed. Fifty patients diagnosed with active steroid‐resistant UC were enrolled in this study from 14 medical centers. Using a centrifugal cell separator (Component Collection System, Haemonetics), leukocyte apheresis was performed once a week for 5 weeks. General conditions and abdominal symptoms were recorded daily, and laboratory tests were followed weekly. Changes of colonoscopic and histological manifestations of luminal activity through the study period were evaluated. At the end of the study period, stool frequency was decreased to less than 4 times a day in 68.4% (26 of 38) and serum C‐reactive protein (CRP) concentration was normalized in 56.7% (17 of 30) of the patients. Colonoscopic remission was achieved in 57.7% (26 of 45), and histological improvement was noted in 54.1% (20 of 37) of the patients tested. Improved disease activity was demonstrated in 74% (37 of 50) of the patients by general assessment criteria. Analysis of the trial data confirmed the valid clinical efficacy of leukocyte apheresis by centrifugal cell separator in refractory UC patients.     

钙卫蛋白、乳铁蛋白在溃疡性结肠炎患者中表达的临床研究

背景:溃疡性结肠炎(UC)是慢性反复发作的肠道炎性疾病,评估疾病活动度对其疗效判断非常重要,实验室标记物尤其是粪便标记物可很好地反映疾病活动度。目的:探讨钙卫蛋白(Cal)、乳铁蛋白(Lf)在UC患者结肠黏膜和粪便中表达的临床意义。方法:选取1998年1月～2008年1月安徽医科大学第一附属医院收治的具备完整结肠镜或手术病理检查结果的UC患者120例。以临床活动度指数(CAI)评分进行疾病分期,以免疫组化SP法检测结肠黏膜Cal、Lf表达,以ELISA法检测粪便Cal、Lf含量。结果:活动期UC患者结肠黏膜中均表达Cal、Lf,缓解期无或仅弱表达。活动期UC患者粪便Cal、Lf含量显著高于缓解期(P0.01)。UC患者结肠黏膜Cal和Lf表达以及粪便Cal和Lf含量均与CAI评分呈正相关(P=0.000)。粪便Cal和Lf含量与结肠黏膜Cal和Lf表达亦呈正相关(r=0.588,P=0.000;r=0.519,P=0.000),且判断UC活动性的敏感性和特异性均较高。结论:UC患者结肠黏膜Cal、Lf表达可反映临床严重度,粪便Cal、Lf含量与UC活动性显著相关。     

Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis: A Pilot Study

The effect of granulocyte and monocyte adsorption apheresis (GMA) on prevention of relapse of ulcerative colitis (UC) is not clear. This was a pilot open‐labeled, prospective, randomized, unblinded study to compare the tolerability and efficacy of intermittent GMA (once every 2 weeks) with mercaptopurine to maintain remission of UC. Twenty‐one patients with UC, who had achieved remission by induction therapies were randomly assigned to receive either intermittent GMA (N = 10) or oral mercaptopurine (0.5 mg/kg per day; N = 11). The study period was 24 months. The rate of the patients maintaining remission and the incidences of adverse effects were compared between the two groups. At 24 months, seven of 10 patients (70.0%) on intermittent GMA and seven of 11 patients (63.6%, P = 1.00) on oral mercaptopurine were still in remission. Three patients relapsed in each group. One patient taking mercaptopurine, but none receiving intermittent GMA, dropped out because of adverse effects. Intermittent therapy with GMA was well tolerated and a substantial proportion of patients maintained remission. Intermittent GMA therapy in maintaining remission of UC merits further investigation.     

Effect of Budesonide Enema on Remission and Relapse Rate in Distal Ulcerative Colitis and Proctitis

Background: Glucocorticosteroid enemas are equally effective as 5-ASA enemas in the treatment of active distal ulcerative colitis (UC). With the introduction of budesonide, the risk of systemic side effects may be reduced. We investigated whether budesonide enema, 2 mg/100 ml, administered twice daily (b.i.d.) could increase the remission rate in comparison with the once daily (o.d.) standard regimen. Furthermore, we evaluated whether 2 mg budesonide enema, given twice weekly, could have a relapse preventing effect. Methods: 149 patients with active distal UC were treated in a controlled, double-blind multicentre study with two parallel groups: placebo enema in the morning and budesonide enema in the evening (i.e. 2 mg/day) or budesonide enema b.i.d. (i.e. 4 mg/day) until remission (absence of clinical symptoms and endoscopic healing) or at most 8 weeks. Patients in remission were randomized to either budesonide enema or placebo enema twice weekly for 24 weeks or until relapse. Results: The remission rates at 4 weeks were 33% for o.d. and 41% for b.i.d. regimens (NS) and correspondingly 51% and 54% at 8 weeks (NS). The b.i.d. group had an increased frequency of impaired adrenal function, 32% versus 4.8% ( P = 0.001). The relapse rates during maintenance treatment with budesonide enema and placebo were 15% versus 24% after 8 weeks, 31% versus 27% after 16 weeks and 41% versus 51% after 24 weeks (NS). Conclusion: Budesonide enema 2 mg o.d. appears to be the optimal dosage in active distal UC. We could not show that budesonide enema twice weekly is sufficient to maintain remission.     

双歧杆菌、乳杆菌、嗜热链球菌三联活菌片对缓解期溃疡性结肠炎CD4^＋CD25^＋T细胞的影响

背景：CD4^＋CD25^＋T细胞是一种免疫调节细胞,CD4^＋CD25^＋T/CD4^＋T比值在免疫调节中起主要作用,并维持机体的免疫平衡。目的：探讨双歧杆菌、乳杆菌、嗜热链球菌三联活菌片对缓解期溃疡性结肠炎（UC）患者CD4^＋CD25^＋T细胞的影响。方法：33例缓解期UC患者分为UC对照组和UC治疗组,后者予双歧杆菌、乳杆菌、嗜热链球菌三联活菌片,并设正常对照组。治疗后行症状和内镜评分,以流式细胞仪检测外周血单个核细胞（PBMC）和肠黏膜中CD4^＋CD25^＋T细胞和CD4^＋T细胞比例,以实时定量逆转录聚合酶链反应（RT-PCR）检测PBMC和肠黏膜中Foxp3 mRNA含量。结果：UC对照组症状和内镜评分与UC治疗组相比均无明显差异。与正常对照组相比,UC对照组患者PBMC中CD4^＋CD25^＋T/CD4^＋T比值显著增高（P〈0.05）,肠黏膜中CD4^＋CD25^＋T/CD4^＋T比值显著降低（P〈0.05）。与UC对照组相比,UC治疗组患者PBMC中CD4^＋CD25^＋T/CD4^＋T比值显著降低（P〈0.05）,肠黏膜中CD4^＋CD25^＋T/CD4^＋T比值显著增高（P〈0.05）,与正常对照组无明显差异。三组间PBMC和肠黏膜中Foxp3 mRNA含量无明显差异。结论：缓解期UC患者CD4^＋CD25^＋T/CD4^＋T比值发生改变,表明免疫调节功能出现异常。双歧杆菌、乳杆菌、嗜热链球菌三联活菌片具有免疫调节作用,可使CD4^＋CD25^＋T/CD4^＋T比值恢复正常。     

缺血性结肠炎与溃疡性结肠炎的临床鉴别诊断

背景:缺血性结肠炎(IC)与溃疡性结肠炎(UC,左半结肠型)在临床和内镜表现上有一定相似之处,对于临床表现不典型者,初步诊断颇具难度。目的:分析IC与UC的临i床鉴别诊断要点。方法:收集武汉大学中南医院2008年1月～2009年12月确诊为IC或UC左半结肠炎的住院患者,对其病史资料进行回顾性分析。结果:21例IC和25例UC患者纳入研究。IC患者以老年女性居多,病程相对较短,常伴有高血压和糖尿病,最突出的临床表现为突发腹痛后24 h内出现便血,贫血少见;UC患者的主要临床表现为黏液血便伴腹痛,贫血常见。IC病变多仅累及单一肠段,直肠受累少见,溃疡小而表浅,病理学表现为慢性炎,隐窝炎罕见;UC病变多起源于直肠,呈连续性,溃疡弥漫,病理学表现为慢性炎伴多种炎性细胞浸润,隐窝炎、隐窝脓肿常见。结论:根据性别、年龄、病程以及临床、实验室、内镜和病理检查结果进行综合分析,有助于IC与U C的鉴别诊断。     

微生态制剂对溃疡性结肠炎疗效的系统评价

背景：溃疡性结肠炎（UC）是一种病因尚未明确的慢性非特异性肠道炎症,微生态制剂在UC的治疗中起重要作用。目的：对微生态制剂联合标准方案（氨基水杨酸类制剂或糖皮质激素）治疗UC的疗效进行系统评价。方法：计算机检索Cochrane图书馆（截至2011．8）、MEDLINE（1966．11～2011．8）、EMBASE（1975．10－2011．8）、中国生物医学文献光盘数据库（1979．11-2011．8）和中文期刊全文数据库（1985．4－2011．8）等数据库．纳入微生态制剂组（微生态制剂联合标准方案）与对照组（标准方案联合安慰剂或空白对照）治疗UC的随机对照试验（RCT）,采用RevMan4．2软件行系统分析。结果：共纳入8项RCT,包括533例患者。微生态制剂组的UC临床缓解率和总有效率明显优于对照组,OR分别为2．48（95％CI：1．54－4．00）和7．38（95％CI：1．65～33．06）,临床有效率无明显差异（OR=2．64．95％CI：0．46～5．88）,而复发率明显低于对照组（OR=0．22,95％CI：0．05。0．87）。结论：微生态制剂联合标准方案对诱导和维持UC缓解的疗效优于单用标准方案．     

溃疡性结肠炎患者手术治疗预测因素分析

手术是溃疡性结肠炎（UC）内科治疗无效或发生严重并发症者的治疗选择.目的：分析UC患者行手术治疗的可能预测因素.方法：纳入1998年8月～2009年9月北京协和医院住院UC患者312例,其中34例接受手术治疗,278例接受非手术治疗,回顾性分析、比较两组患者的各类临床资料.结果：住院UC患者手术率为10.9%,手术死亡率为5.9%,重度UC患者手术率为23.9%.手术组13例患者为激素抵抗,8例为激素依赖,9例发生严重并发症,4例激素治疗有效者主动要求手术治疗.手术组平均住院次数显著多于非手术组（P〈0.05）,术前Hb、白蛋白显著低于非手术组（P〈0.05）,CRP显著高于非手术组（P〈0.05）,重度结肠炎、全结肠炎患者比例显著高于非手术组（P〈0.05）.结论：疾病严重程度高、病变范围广、对激素抵抗的UC患者,手术需求增加.     

克罗恩病术后治疗和溃疡性结肠炎手术时机的抉择

炎症性肠病(IBD)包括克罗恩病(CD)和溃疡性结肠炎(UC),是一种肠道慢性非特异性炎症性疾病。尽管治疗IBD的药物层出不穷,但仍有部分患者需行手术治疗。CD的术后治疗和UC手术时机的选择对患者的生活质量的提高以及预后非常重要。本文就CD的术后治疗和UC手术时机的选择作一简单概述。